Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COTI-2 in advanced or recurrent malignancies
NCT02433626Phase 1Unknown
- Sponsor
- Cotinga Pharmaceuticals
- Start
- Dec 2015
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of COTI-2 in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC) and 6 more (2 arms), sponsored by Cotinga Pharmaceuticals. Primary endpoints: Number of Dose Limiting Toxicities at 12 months and Time to Maximum Plasma Concentration at 6 months. Status: unknown.
02
Drugs
COTI-2
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)endometrial cancer (EC)Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT02433626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02433626.